Company Description
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain.
It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body’s peripheral nervous system.
The company’s lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy.
It also develops CT2000 as a topical agent for the treatment of both acute and chronic eye pain; and CT3000 to treat post operative pain with the use of nerve blocks.
The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024.
Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Francis Knuettel |
Contact Details
Address: 4400 Route 9 South, Suite 1000 Freehold, New Jersey 07728 United States | |
| Phone | 877 265 8266 |
| Website | channeltherapeutics.com |
Stock Details
| Ticker Symbol | PTHS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001919246 |
Key Executives
| Name | Position |
|---|---|
| Francis Knuettel | Chief Executive Officer |
| Francis Knuettel | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 3, 2025 | SCHEDULE 13D/A | Filing |
| Jul 3, 2025 | SCHEDULE 13D | Filing |
| Jul 2, 2025 | 8-K | Current Report |
| May 27, 2025 | DEFM14C | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 9, 2025 | PREM14C | Filing |
| May 1, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 8-K | Current Report |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |